Short, frequent, 5-days-per-week, in-center hemodialysis versus 3-days-per week treatment: a randomized crossover pilot trial through the Midwest Pediatric Nephrology Consortium

Pediatr Nephrol. 2017 Aug;32(8):1423-1432. doi: 10.1007/s00467-017-3656-x. Epub 2017 Apr 8.

Abstract

Background: No controlled trials in children with end-stage kidney disease have assessed the benefits of more frequently administered hemodialysis (HD).

Methods: We conducted a multicenter, crossover pilot trial to determine if short, more frequent (5 days per week) in-center HD was feasible and associated with improvements in blood pressure compared with three conventional HD treatments per week. Because adult studies have not controlled for the weekly duration of dialysis, we fixed the total treatment time at 12 h a week of dialysis during two 3-month study periods; only frequency varied from 5 to 3 days per week between study periods.

Results: Eight children (median age 16.7 years) consented at three children's hospitals. The prespecified primary composite outcome was a sustained 10% decrease in systolic blood pressure and/or a decrease in antihypertensive medications relative to each study period's baseline. Among the six patients completing both study periods, five (83.3%) experienced the primary outcome during HD performed 5 days per week but not 3 days per week; one of the six (16.7%) achieved that outcome during 3-day but not 5-day (p = 0.22) per week HD. During 5-day HD, all patients had significantly more treatments during which their pre-HD systolic (p = 0.01) or diastolic (p = 0.01) blood pressure was 10% lower than baseline.

Conclusions: We observed that more frequent HD sessions per week was feasible and associated with improved blood pressure control, but barriers to changing thrice-weekly standard of care include financial reimbursement and the time demands associated with more frequent treatments.

Keywords: Children; End-stage kidney disease; Hypertension; More frequent hemodialysis.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Antihypertensive Agents / therapeutic use*
  • Blood Pressure Determination
  • Cross-Over Studies
  • Feasibility Studies
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / etiology
  • Insurance, Health, Reimbursement
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy*
  • Male
  • Midwestern United States
  • Nephrology
  • Pilot Projects
  • Renal Dialysis / economics*
  • Renal Dialysis / methods*
  • Time Factors
  • Treatment Outcome

Substances

  • Antihypertensive Agents